These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 26259849)

  • 1. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
    Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
    Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE.
    Poulos C; Kinter E; van Beek J; Christensen K; Posner J
    Int J Technol Assess Health Care; 2018 Jan; 34(4):425-433. PubMed ID: 30251947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.
    Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Gleißner E; Mühlbacher A; Kieseier B
    Ther Adv Neurol Disord; 2016 Mar; 9(2):95-104. PubMed ID: 27006697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' preferences and willingness-to-pay for disease-modifying therapies.
    Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
    Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
    Bottomley C; Lloyd A; Bennett G; Adlard N
    J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis.
    Shingler SL; Swinburn P; Ali S; Perard R; Lloyd AJ
    J Med Econ; 2013 Aug; 16(8):1036-42. PubMed ID: 23730944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
    Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
    Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
    Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
    Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment.
    Bandari D; Adamson M; Bowman M; Gutierrez A; Athavale A; Oak B; Hadker N; Branco F; Geremakis C; Lewin JB; Shankar SL
    J Med Econ; 2023; 26(1):1507-1518. PubMed ID: 37934412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis.
    Hincapie AL; Penm J; Burns CF
    J Manag Care Spec Pharm; 2017 Aug; 23(8):822-830. PubMed ID: 28737987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
    Fifer S; Rose J; Hamrosi KK; Swain D
    BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment.
    Levitan B; Markowitz M; Mohamed AF; Johnson FR; Alphs L; Citrome L; Bridges JF
    Psychiatr Serv; 2015 Jul; 66(7):719-26. PubMed ID: 25772762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient and parent preferences for immunoglobulin treatments: a conjoint analysis.
    Mohamed AF; Kilambi V; Luo MP; Iyer RG; Li-McLeod JM
    J Med Econ; 2012; 15(6):1183-91. PubMed ID: 22846048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments.
    Janssen EM; Hauber AB; Bridges JFP
    Value Health; 2018 Jan; 21(1):59-68. PubMed ID: 29304942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
    González JM; Doan J; Gebben DJ; Boeri M; Fishman M
    Pharmacoeconomics; 2018 Aug; 36(8):973-986. PubMed ID: 29869777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chinese patients' preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment.
    Si L; Tu L; Xie Y; Palmer AJ; Gu Y; Zheng X; Li J; Lv Q; Qi J; Lin Z; Chen M; Gu J; Hiligsmann M
    Arch Osteoporos; 2019 Jul; 14(1):85. PubMed ID: 31367860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
    Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
    Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferences for Multiple Sclerosis Treatments: Using a Discrete-Choice Experiment to Examine Differences Across Subgroups of US Patients.
    Mansfield C; Thomas N; Gebben D; Lucas M; Hauber AB
    Int J MS Care; 2017; 19(4):172-183. PubMed ID: 28835741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
    Higuera L; Carlin CS; Anderson S
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.